Loading
A phase 2 trial of Capecitabine, Oxaliplatin, Disitamab vedotin and Toripalimab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. is a phase 2 interventional study registered as NCT06155383 by RemeGen Co., Ltd., with 90 participants planned, started 2023-11-27 and due to reach its primary completion in 2025-01-31. Interventions recorded: Capecitabine, oxaliplatin, Disitamab Vedotin and Toripalimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RemeGen, Disitamab vedotin, HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Oxaliplatin, Capecitabine and the tag pipeline.
Shares RemeGen, Toripalimab, Oxaliplatin, Capecitabine and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/